 Trial is designed to advance pelareoreps clinical development in China, the worlds second-largest pharmaceutical market SAN DIEGO and CALGARY, AB, Oct. 14, 2021 PRNewswire -- Oncolytics Biotech Inc. NASDAQ: ONCY TSX: ONC today announced that its partner Adlai Nortye has initiated dosing in a bridging clinical trial evaluating the safety, tolerability, and preliminary efficacy of pelareorep-paclitaxel combination therapy in Chinese patients with advanced or metastatic breast cancer. Results from the bridging trial are expected to allow Adlai Nortye to include data from Oncolytics North American metastatic breast cancer trials in a future submission to Chinese regulators. 